Introduction
============

Acute hyperglycemia and insulin resistance are characteristics of metabolic and endocrine imbalances of critically ill patients and are subject to a substantial inflammatory response that is partly mediated by cytokines produced by peripheral blood mononuclear cells (PBMC). Treatment with intensive insulin therapy to keep patients normoglycemic has been shown to reduce inflammatory responses. It is unclear whether hyper-glycemia, insulin or osmolarity changes exert direct effects on proinflammatory cytokines. We investigated the direct effects of these substances on cytokine production of PBMC *in vitro*.

Methods
=======

PBMC were isolated from peripheral blood of 10 healthy volunteers via Ficoll gradient. Cells were incubated for 3 hours at 37°C with/without low/high concentrations of glucose, mannitol, urea, insulin and stimulated with 0.5 ng/ml LPS. After 24 hours, concentrations of IL-6 and IL-1β were measured with an ELISA method.

Results
=======

Increasing concentrations of glucose, mannitol and urea resulted in a significant increase of IL-6 and IL-1β cytokine production. Insulin had no effect (Table [1](#T1){ref-type="table"}).

  Substance   No supplementation   Low concentration   High concentration
  ----------- -------------------- ------------------- --------------------
  Glucose     1,726                \-                  9,643
  Insulin     609                  555                 636
  Urea        2,056                3,421               3,835
  Mannitol    367                  \-                  3,269

Conclusion
==========

High concentrations of glucose, mannitol and urea lead to a significant increase in IL-6 and IL-1β cytokine production by PBMC *in vitro*. The most profound effect was seen with hyperglycemia. Besides hyperglycemia, also uremia and high osmolarity seem to augment inflammation. Insulin could not reverse the increase in inflammation. These findings may be relevant in explaining the beneficial effects of normoglycemia on the inflammatory response in critically ill patients.
